Anorexia Nervosa Clinical Trial
Official title:
Examining the Effects of Reduced Environmental Stimulation on Eating Disorders
NCT number | NCT02801084 |
Other study ID # | 2015-002-01 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | April 2016 |
Est. completion date | October 19, 2017 |
Verified date | October 2020 |
Source | Laureate Institute for Brain Research, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The study proposed in this protocol aims to document the physiological, subjective, behavioral, and neural effects of reduced environmental stimulation (floating) in patients with current or prior anorexia nervosa The primary aim of this study is to determine the safety of this intervention. Secondary aims including determining whether floating has an impact on symptom reports such as those related to anxiety and eating disorders.
Status | Completed |
Enrollment | 21 |
Est. completion date | October 19, 2017 |
Est. primary completion date | October 19, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: 1. Current or prior diagnosis of anorexia nervosa (AN) 2. All AN participants must be weight-restored prior to their participation, defined as having a Body Mass Index (BMI) > 17.5 Exclusion Criteria: 1. Any of the following DSM-V disorders: 1. Schizophrenia Spectrum and Other Psychotic Disorders 2. Bipolar and Related Disorders 2. Currently being treated for their psychiatric condition as an inpatient. 3. Active suicidal ideation with intent or plan (as determined by a psychiatrist or clinical psychologist for all participants who report an IDAS-II suicide score > 10). 4. Morbid obesity (BMI > 40) or underweight (BMI < 17.5). 5. Orthostatic hypotension (defined as a drop of =20 mm Hg in systolic blood pressure or a drop of =10 mm Hg in diastolic blood pressure when measured shortly after transitioning from lying down to standing). 6. Certain drugs or medications consumed within the past week including any psychoactive drugs (e.g., MDMA, LSD, psilocybin, peyote, phencyclidine, ketamine), magnesium supplements (greater than 150mg) or milk of magnesia. Any antihistamine that causes drowsiness (e.g., Benadryl) or any alcohol consumed within the past 12 hours. Caffeine or nicotine consumed within the past 3 hours. For all other medications, participants must be stably medicated prior to participation (defined as having taken the medication for 6 weeks or longer). 7. History of unstable liver or renal insufficiency; glaucoma; diabetes; significant and unstable cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, or metabolic disturbance. 8. Pregnancy as detected by a urine test. 9. Failure to adhere to "Pre-float checklist". 10. Non-correctable vision or hearing problems. |
Country | Name | City | State |
---|---|---|---|
United States | Laureate Institute for Brain Research | Tulsa | Oklahoma |
Lead Sponsor | Collaborator |
---|---|
Laureate Institute for Brain Research, Inc. |
United States,
Khalsa SS, Moseman SE, Yeh HW, Upshaw V, Persac B, Breese E, Lapidus RC, Chappelle S, Paulus MP, Feinstein JS. Reduced Environmental Stimulation in Anorexia Nervosa: An Early-Phase Clinical Trial. Front Psychol. 2020 Oct 6;11:567499. doi: 10.3389/fpsyg.20 — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Orthostatic blood pressure | Defined as a drop of =20 mm Hg in systolic blood pressure or a drop of =10 mm Hg in diastolic blood pressure when measured shortly after transitioning from lying down to standing. | Immediately before and after each float session for 4 float sessions, spaced weekly to monthly for up to 16 weeks study duration | |
Secondary | Self-ratings of changes in emotional experience | Measured via self-report measure (Positive and Negative Affect Schedule X) | Immediately before and after each float session for 4 float sessions, spaced weekly to monthly for up to 16 weeks study duration | |
Secondary | Self-ratings of changes in physical experience | Interoceptive and exteroceptive sensations, measured via visual analogue scale (e.g., 0 to 100) | Immediately before and after each float session for 4 float sessions, spaced weekly to monthly for up to 16 weeks study duration | |
Secondary | Body image | Measured via Photographic Figure Rating Scale, Body Appreciation Scale, Body Image States Scale, Body Shape Questionnaire, visual analogue scale (e.g., 0 to 10). | Obtained at baseline and immediately after each float session for 4 float sessions, spaced weekly to monthly for up to 16 weeks study duration | |
Secondary | EEG changes during the float experience | May be measured during the first, second, and fourth float. | During the first, second, and fourth float for 4 float sessions, spaced weekly to monthly for up to 16 weeks study duration | |
Secondary | Heart rate variability during the float experience | Measured during the first, second, and fourth float. | Obtained at baseline and after the first, second, and fourth float for 4 float sessions, spaced weekly to monthly for up to 16 weeks study duration | |
Secondary | Eating disorder severity | Measured via the Eating Disorder Examination Questionnaire | Obtained during the first visit | |
Secondary | Trauma exposure | Measured via the Childhood Trauma Questionnaire | Obtained during the first visit | |
Secondary | Self-ratings of changes in anxiety | Measured via self-report measure (Spielberger State-Trait Anxiety Index) | Obtained at baseline and immediately before and after each float session for 4 float sessions, spaced weekly to monthly for up to 16 weeks study duration | |
Secondary | Self-ratings of anxiety sensitivity | Measured via the Anxiety Sensitivity Index | Obtained during the first visit |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05531604 -
Appetitive Conditioning in Anorexia Nervosa
|
||
Enrolling by invitation |
NCT04174703 -
Preparing for Eating Disorders Treatment Through Compassionate Letter-Writing
|
N/A | |
Active, not recruiting |
NCT04883554 -
Impact of an Olfactory Sensory Therapeutic Group for Adolescent Patients With Restrictive Anorexia Nervosa , Pilot Study
|
N/A | |
Recruiting |
NCT04213820 -
TMS and Body Image Treatment for Anorexia Nervosa
|
N/A | |
Completed |
NCT03414112 -
The Impact of Oxytocin on the Neurobiology of Anorexia Nervosa
|
Early Phase 1 | |
Recruiting |
NCT06144905 -
Norwegian Microbiota Study in Anorexia Nervosa
|
||
Recruiting |
NCT05803707 -
Home-based Adapted Physical Activity in Anorexia Nervosa: a Feasibility Pilot Study
|
N/A | |
Recruiting |
NCT05682417 -
Impact of Body Schema Distortion on Remission and Weight Regain in Anorexia Nervosa
|
N/A | |
Not yet recruiting |
NCT06380257 -
Anorexia Nervosa and Brain in Adolescence
|
||
Not yet recruiting |
NCT04804800 -
Virtual Reality Place in the Management of Body Dysmorphia Disorders in Anorexia Nervosa
|
N/A | |
Not yet recruiting |
NCT03600610 -
Evaluation of CARdiac Abnormalities by Echocardiography and MRI in Malnourished Patients Suffering From Anorexia Nervosa
|
N/A | |
Completed |
NCT02745067 -
Effectiveness of Enhanced Cognitive Behavioral Therapy (CBT-E) in the Treatment of Anorexia Nervosa
|
N/A | |
Completed |
NCT02382055 -
Changing Habits in Anorexia Nervosa: Novel Treatment Development
|
N/A | |
Completed |
NCT03075371 -
Homeostatic and Non-homeostatic Processing of Food Cues in Anorexia Nervosa
|
N/A | |
Terminated |
NCT02240797 -
Kappa Opioid Receptor Imaging in Anorexia
|
N/A | |
Unknown status |
NCT01761942 -
Fatty Acids Omega -3 Diet Supplementation Efficiency and Safety Evaluation in Anorexia Nervosa
|
Phase 2 | |
Completed |
NCT03144986 -
Insula-coil Deep TMS for Treatment Resistant Anorexia Nervosa
|
N/A | |
Completed |
NCT01579682 -
Adaptive Family Treatment for Adolescent Anorexia Nervosa
|
N/A | |
Completed |
NCT02551445 -
A fMRI Pilot Study of the Effects of Meal-support in Eating Disorders.
|
N/A | |
Completed |
NCT00946816 -
The Effects of Dietary Intervention on Gastrointestinal Function in Patients With Anorexia Nervosa and Obesity
|
N/A |